Background: The regulation and function of IgE in healthy individuals and in antigen-naı¨ve animals is not well understood. IL-33 administration increases serum IgE in mice with unknown mechanism. We tested the hypothesis that IL-33 provides an antigen-independent stimulus for IgE production and mast cell degranulation. Methods: IL-33 was administered to naı¨ve wild-type (WT), nude and ST2 À/À ,
ST2
À/À , IL-4 À/À , IL-4Ra À/À or B-cell-specific IL-4Ra À/À mice, demonstrating IL-33 specificity and IL-4 dependency. Moreover, IL-4 was required for IL-33-induced B-cell proliferation and T-cell CD40L expression, which promotes IgE production. IL-33-induced IL-4 production was mainly from innate cells including mast cells and eosinophils. IL-33 increased mast cell surface IgE and triggered degranulation and systemic anaphylaxis in allergen-naı¨ve WT but not in IL-4Ra À/À mice.
Conclusion: IL-33 amplifies IgE synthesis and triggers anaphylaxis in naı¨ve mice via IL-4, independent of allergen. IL-33 may play an important role in nonatopic allergy and idiopathic anaphylaxis.
IgE antibody is induced by allergen and requires immunoglobulin heavy-chain class switching and affinity maturation in B cells in a T-cell-dependent manner (1, 2) . IgE is also produced naturally (1, 3) but less is known about the selective amplification and function of natural IgE in healthy subjects and antigen-naı¨ve animals (3) . Natural IgE is secreted by B2 cells and contributes to the baseline concentrations of nonallergen-specific IgE in the serum and tissues of healthy individuals (3, 4) . In contrast to allergen-induced IgE, cognate T-helper cell via MHC class II and somatic hypermutation are not required for the generation of natural IgE (3). Instead, bystander stimulation from T-cell CD40L and low levels of IL-4 are necessary (3, 4) . The functions of natural IgE are poorly understood; they are polyreactive and have a critical role in immune priming (3) (4) (5) (6) (7) . IgE can bind the high-affinity IgE receptor (FceRI) and prolong mast cell survival, release a spectrum of cytokines and have important roles in defence against infection and initiation of adaptive immunity (5) (6) (7) (8) .
IL-33 is a new IL-1 family member and signals via a receptor complex consisting of ST2 (IL-1LR1) and IL-1RAcP (9, 10) . IL-33 is expressed by innate cells in humans and mice, primarily epithelium and endothelium, and can be released when cells sense inflammatory signals or undergo (9) (10) (11) . ST2 is expressed by most innate cells but only by selected adaptive immune cells (9, 12, 13) . Thus, IL-33 can directly activate eosinophils, basophils, macrophages and NK cells via ST2 (9, (14) (15) (16) . In contrast, ST2 is selectively expressed on IL-5 + Th, Th2 but not Th1 or Th17 cells (17) (18) (19) . While enhancing mature Th2-cell function, IL-33 cannot polarize Th2 cells (17) . Interestingly, IL-33 can induce IgE production in naı¨ve mice (9) . However, the effect and mechanism by which IL-33 induces IgE production in naı¨ve mice is largely unknown.
We aim to identify the mechanism and role of IL-33 in the induction and regulation of IgE production in allergen-naı¨ve mice. We report that IL-33 amplifies IgE synthesis via IL-4 from innate immune cells that is sufficient to trigger mast cell degranulation and anaphylaxis in the absence of allergen. Mice were housed in specific-pathogen-free conditions at Glasgow University, UK, and Cape Town University, South Africa, in accordance with animal experimentation guidelines.
Materials and methods

Mice
IL-33 treatment in vivo
Recombinant IL-33 was prepared as described (23) . Mice were injected i.p. with IL-33 (2 lg/mouse) or PBS daily for 1-7 days unless stated otherwise. Cells were collected by peritoneal washout with 2 ml of cold PBS. Anaphylaxis (AS): Mice were injected i.p. with IL-33 (2 lg) or PBS daily for 3-4 days. Changes in clinical signs and temperature were monitored every 10 min after each injection, using a rectal probe (Natsume Seisakusyo Co., Tokyo, Japan). Plasma histamine was measured by ELISA (IBL, Hamburg, Germany).
Flow cytometry
Cells (3 9 10 5 cells/tube) were stained with fluorochromeconjugated antibodies anti-CD3, anti-CD4, anti-CD19, antiFceRI, anti-CD40L, anti-CD25, anti-CD117 and Siglec-F and isotype controls (BD Bioscience, Oxford, UK). Intracellular cytokine levels in peritoneal cells were determined by staining with anti-IL-4-PE after activation (PMA/ionomycin) and permeabilization. Cells were analysed by FACSCalibur using Cell Quest software (BD Bioscience).
Cytokine and IgE measurements
Serum concentrations of cytokines were determined by Luminex (Luminex, Biosource; Invitrogen, Life Technologies Ltd, Paisley, UK) and IgE by ELISA (Bethyl Laboratories, Inc, Montgomery, TX, USA).
Histological analysis of mast cells
Skin samples were stained with toluidine blue to identify and count mast cells by microscopy. Degranulated mast cells were identified as those with >10% extrusion of granules (20) .
Statistical analysis
Student's t-test was applied to in vitro studies. Analysis between individuals in groups in vivo was carried out by ANOVA followed by Student's t-test. Thus, IL-4 is necessary and sufficient for the induction of IgE by IL-33 in naı¨ve mice.
Results
IL
IL-33 induces type-II cytokines mainly via innate cells in naïve mice
We next investigated whether the increased IL-4 and IL-13 levels in IL-33-treated mice were produced by T cells or innate cells in vivo by comparing WT and athymic nude mice (lacking T cells) injected with IL-33 or PBS as described above. Nude mice produced significantly higher levels of serum IL-4 and IL-13 than IL-33-treated WT mice, but markedly lower IgE ( (Fig. 3C ). Because IL-13 does not directly induce IgE in mouse B cells (24) , together these results suggest that IL-33 indirectly elicits natural IgE production in naı¨ve mice by inducing IL-4, which then directly stimulates B-cell expansion and IgE isotype class switching.
T cells expressing IL-4Ra contribute to IL-33-induced IgE synthesis
Our aforementioned results ( Fig. 2A,B) suggest that T cells also contribute to IL-33-enhanced IgE production in naı¨ve mice other than by providing type-II cytokines. To assess the potential role of IL-4R responses by T cells, we injected (Fig. 4A) . Consistent with the result from nude mice ( Fig. 2A) , IL-33 elicited abundantly increased level of IL-4 and IL-13 in T-IL4Ra À/À compared with WT mice (Fig. 4B ),
suggesting that these cytokines are unlikely to play an important role in T-cell function in IL-33-induced IgE production. An alternative contribution therefore should be considered. (Fig. 4C) . Consistent with our finding (Fig. 3C) , IL-33 also increased the total number of B cells (but not T cells) in the WT but not in IL-4 À/À mice (Fig. 4D) (Fig. 5C) , and a substantial increase in serum histamine levels (Fig. 5D) . Together, these results demonstrate that IL-33 can initiate mast cell degranulation and systemic anaphylaxis in naı¨ve mice via IL4Ra.
Discussion
Data reported in this study reveal a hitherto unrecognized effect and mechanism by which IL-33 induces IgE production and anaphylaxis in the absence of specific allergen (Fig. 6) and hence are not responsive to IL-33 in the absence of T cell receptor activation (17, 18) . In addition, it is known that IL-33 induces mainly IL-5 but not IL-4 in activated T cells and therefore cannot polarize Th2 cells (17) . Using nude mice and T-IL-4Ra-deficient mice, we demonstrated that T cells nevertheless play a significant role in IL-33-derived IgE production in naı¨ve mice. However, this process is unlikely to involve IL-4 production, because nude mice and T-IL-4Ra-deficient mice produced normal or elevated levels of IL-4 and yet had significantly less IgE compared to WT mice. Previous studies have shown that T cells expressing CD40L are required for the induction of which subsequently interacts with B cells to promote IgE production. Anaphylaxis (AS) is an acute, life-threatening allergic reaction in which IgE-mediated mast cell degranulation plays a critical role (28, 29) . The aetiology of AS in particular idiopathic AS is not fully understood (28, 30) . Our result demonstrated for the first time that IL-33/ST2 signals can trigger anaphylaxis in naı¨ve mice in the absence of specific allergen (Fig. 5) . While the detailed molecular mechanism is still unresolved, we found the IL-33-mediated allergen-independent mast cell degranulation and systemic AS described here was dependent on ST2, IL-4Ra and required repeated IL-33 stimulation (Fig. 5C) . Thus, the mechanism may comprise a combination of the following two components: 1 It is known that increased mast cell surface IgE expression and mast cell activation are the hallmark of mast cell degranulation and AS. We found that IL-33 can markedly enhance the levels of serum and mast cell surface IgE that is dependent on ST2 and IL-4Ra in antigen-naı¨ve mice. In addition, mast cells also express high levels of ST2, IL-4Ra and IgE FceR, and it is known that signals via these receptors play critical roles in mast cell activation and function. IL-33 can directly stimulate mast cell proliferation, cytokine production and activation (Fig. 2B , C and ref. 19) , and the signals from the interaction between IL-4/IL-13 and IgE with their receptors can activate and prolong the survival of mast cells as well as can exacerbate AS (6, 8, 31 ). 2 We also found that at least three daily IL-33 treatments were required for IL-33 to trigger mast cell degranulation and AS. Intriguingly, this was also the critical time required for IL-33 to elicit significant production of IgE and IL-4/IL-13 and mast cell proliferation (Figs 1A, 2B,C and 5). Thus, our results suggest that while IL-33, IL-4 or IgE alone is insufficient to trigger mast cell degranulation without allergen, the accumulated number and activation status of mast cells, strong FceR signals derived from continued and intensive interaction between IgE and its high-affinity receptor and repetitive IL-33/ST2 and IL-4Ra signals may cumulatively or synergistically reach a signal threshold that leads to mast cell degranulation and AS.
IL-33 is clearly detected in various clinical allergic diseases including asthma and dermatitis (15, 32, 33) . Given that many allergic reactions occur without a known allergen, including nonatopic asthma and idiopathic anaphylaxis (30, 34) , IL-33 may play a critical role in these diseases. Supporting this hypothesis, we have measured serum IL-33 levels in atopic and nonatopic patients with severe asthma by ELISA. Our results showed that asthma subjects have a wide range of serum IL-33 levels and that there was no significant difference between atopic and nonatopic subjects (Fig. S1 ). This result is consistent with our finding in the animal model, as well as with a recent report that IL33 polymorphism is correlated with clinical asthma but not necessarily atopy (35) . Because IL-4 and IL-13 also play a pivotal role in antigenspecific IgE production, IL-33 may therefore have a general effect on all IgE-mediated allergic conditions. This concept suggests that IL-33 may represent a novel therapeutic target for a range of allergic diseases.
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